Company intelligence / Profile preview
ERX Pharmaceuticals
Cambridge, Massachusetts, USAerxpharmaceuticals.com ↗
- Ownership
- Private
- Employees
- ~10
- Development stage
- Phase 1
01
Overview
ERX-1000, the company's lead drug candidate, has completed a Phase 1 double-blind, placebo-controlled, single and multiple oral dose study in healthy obese and non-obese subjects. In preclinical studies, ERX-1000 showed a 45% reduction in body weight in diet-induced severely obese mice.
- Therapeutic areas
- EndocrinologyRare DiseasesMetabolic Disorders
- Modalities
- Small molecule drugs
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
Boston Children's Hospital
Beyond the preview
Go deeper on ERX Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ERX Pharmaceuticals.